| PHGUF Stock | | | USD 0.76 0.01 1.33% |
Executive
Dr. Bruno M. Giannetti was Member of the Management Board, Chief Operations Officer of Pharming Group NV since December 1, 2006. He has more than 30 years of experience in the pharmaceutical and biotech industry. Previously, he was the CEO of AMPharma BV and President and CEO of Verigen AG, Germany. He has served as senior management consultant for pharmaceutical RD projects at Coopers Lybrand . Dr. Giannetti was also worldwide VicePresident Marketing and Medical Information at Immuno, Austria and Head of Clinical Research at Madaus AG, Germany since 2006.
| Age | 71 |
| Tenure | 18 years |
| Professional Marks | Ph.D |
| Phone | 31 71 524 7400 |
| Web | https://www.pharming.com |
Giannetti holds a PhD in Chemistry, a MD PhD degree in Medicine from the University of Bonn and has recently been appointed Professor at the Pharmaceutical Faculty of the University of Seville .
Pharming Group Management Efficiency
The company has return on total asset
(ROA) of
0.0643 % which means that it generated a profit of $0.0643 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
0.1669 %, meaning that it generated $0.1669 on every $100 dollars invested by stockholders. Pharming Group's management efficiency ratios could be used to measure how well Pharming Group manages its routine affairs as well as how well it operates its assets and liabilities.
Pharming Group NV has accumulated 122.65
M in total debt with debt to equity ratio
(D/E) of 0.75, which is about average as compared to similar companies. Pharming Group NV has a current ratio of 5.12, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Pharming Group until it has trouble settling it off, either with new capital or with free cash flow. So, Pharming Group's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Pharming Group NV sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Pharming to invest in growth at high rates of return. When we think about Pharming Group's use of debt, we should always consider it together with cash and equity.
Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. Pharming Group N.V. is headquartered in Leiden, the Netherlands. Pharming Grp operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 277 people. Pharming Group NV [PHGUF] is a
Pink Sheet which is traded between brokers as part of OTC trading.
Management Performance
Pharming Group NV Leadership Team
Elected by the shareholders, the Pharming Group's board of directors comprises two types of representatives: Pharming Group inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pharming. The board's role is to monitor Pharming Group's management team and ensure that shareholders' interests are well served. Pharming Group's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pharming Group's outside directors are responsible for providing unbiased perspectives on the board's policies.
Pharming Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Pharming Group a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Pharming Pink Sheet
When determining whether Pharming Group NV is a strong investment it is important to analyze Pharming Group's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pharming Group's
future performance.
For an informed investment choice regarding Pharming Pink Sheet, refer to the following important reports: Check out
Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pharming Group NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in employment.
You can also try the
Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Please note, there is a significant difference between Pharming Group's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pharming Group is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pharming Group's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.